These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732 [TBL] [Abstract][Full Text] [Related]
6. The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. Sarasquete ME; García-Sanz R; Armellini A; Fuertes M; Martín-Jiménez P; Sierra M; Del Carmen Chillón M; Alcoceba M; Balanzategui A; Ortega F; Hernández JM; Sureda A; Palomera L; González M; San Miguel JF Haematologica; 2006 Nov; 91(11):1551-4. PubMed ID: 17043023 [TBL] [Abstract][Full Text] [Related]
7. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Chang H; Yeung J; Xu W; Ning Y; Patterson B Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615 [TBL] [Abstract][Full Text] [Related]
8. Low-risk identification in multiple myeloma using a new 14-gene model. Chen T; Berno T; Zangari M Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863 [TBL] [Abstract][Full Text] [Related]
9. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Guillerm G; Depil S; Wolowiec D; Quesnel B Haematologica; 2003 Apr; 88(4):476-8. PubMed ID: 12681979 [No Abstract] [Full Text] [Related]
10. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. Decaux O; Lodé L; Magrangeas F; Charbonnel C; Gouraud W; Jézéquel P; Attal M; Harousseau JL; Moreau P; Bataille R; Campion L; Avet-Loiseau H; Minvielle S; J Clin Oncol; 2008 Oct; 26(29):4798-805. PubMed ID: 18591550 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568 [TBL] [Abstract][Full Text] [Related]
12. DNA methylation changes in multiple myeloma. Galm O; Wilop S; Reichelt J; Jost E; Gehbauer G; Herman JG; Osieka R Leukemia; 2004 Oct; 18(10):1687-92. PubMed ID: 15318245 [TBL] [Abstract][Full Text] [Related]
13. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ; Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371 [TBL] [Abstract][Full Text] [Related]